LON:AZN AstraZeneca (AZN) Share Price, News & Analysis £104.36 +62.00 (+0.60%) As of 05/23/2025 12:30 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityBuy This Stock About AstraZeneca Stock (LON:AZN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AstraZeneca alerts:Sign Up Key Stats Today's Range£102.88▼£105.1450-Day Range 9,669.50▼£118.0852-Week Range 9,573.51▼£133.88Volume3.09 million shsAverage Volume15.58 million shsMarket Capitalization£200.79 billionP/E Ratio28.61Dividend Yield2.24%Price TargetGBX 6,303.50Consensus RatingModerate Buy Company OverviewAstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.Read More… AstraZeneca Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreAZN MarketRank™: AstraZeneca scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.3 / 5Analyst RatingModerate Buy Consensus RatingAstraZeneca has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAstraZeneca has only been the subject of 2 research reports in the past 90 days.Read more about AstraZeneca's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of AstraZeneca is 28.61, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.52.Price to Earnings Ratio vs. SectorThe P/E ratio of AstraZeneca is 28.61, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.98.Price to Earnings Growth RatioAstraZeneca has a PEG Ratio of 0.86. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioAstraZeneca has a P/B Ratio of 3.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for AZN. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldAstraZeneca pays a meaningful dividend of 1.23%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAstraZeneca does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of AstraZeneca is 64.14%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about AstraZeneca's dividend. Sustainability and ESG4.0 / 5Environmental Score-2.35 Short InterestThere is no current short interest data available for AZN. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for AstraZeneca this week, compared to 3 articles on an average week.Search InterestOnly 14 people have searched for AZN on MarketBeat in the last 30 days. This is a decrease of -39% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AstraZeneca insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.04% of the stock of AstraZeneca is held by insiders.Percentage Held by Institutions51.03% of the stock of AstraZeneca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AstraZeneca's insider trading history. Receive AZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter. Email Address AZN Stock News HeadlinesAstraZeneca climbs Friday, outperforms marketMay 16, 2025 | marketwatch.comIs AstraZeneca (AZN) the Best Pharma Stock to Invest in Amid the Domestic Manufacturing Boom?May 13, 2025 | msn.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.May 25, 2025 | Porter & Company (Ad)Why did the AstraZeneca share price just fall, and what should we do?May 12, 2025 | msn.comAstraZeneca Reports Positive Data From Cancer Drug Trial: Retail Sentiment BrightensMay 9, 2025 | msn.comAstraZeneca advances Friday, outperforms marketMay 9, 2025 | marketwatch.comAstraZeneca slides Wednesday, underperforms marketMay 7, 2025 | marketwatch.comAstraZeneca Gets Approval For Oncology Drug To Treat Mantle Cell Lymphoma In EU: But Retail Sentiment DipsMay 6, 2025 | msn.comSee More Headlines AZN Stock Analysis - Frequently Asked Questions How have AZN shares performed this year? AstraZeneca's stock was trading at £104.68 at the beginning of 2025. Since then, AZN stock has decreased by 0.3% and is now trading at £104.36. View the best growth stocks for 2025 here. How do I buy shares of AstraZeneca? Shares of AZN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of AstraZeneca own? Based on aggregate information from My MarketBeat watchlists, some other companies that AstraZeneca investors own include GSK (GSK), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Intel (INTC), Advanced Micro Devices (AMD) and Johnson & Johnson (JNJ). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - General Sub-IndustryPharmaceutical Products Current SymbolLON:AZN CIKN/A Webwww.astrazeneca.com Phone+44-20-73045000FaxN/AEmployees83,500Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 6,303.50 High Stock Price Target£140 Low Stock Price TargetGBX 74 Potential Upside/Downside-39.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 364.83 Trailing P/E Ratio28.61 Forward P/E Ratio14.30 P/E Growth0.86Net Income£8.71 billion Net Margins13.01% Pretax MarginN/A Return on Equity17.76% Return on Assets7.68% Debt Debt-to-Equity Ratio73.83 Current Ratio0.93 Quick Ratio0.59 Sales & Book Value Annual Sales£66.95 billion Price / Sales3.00 Cash FlowGBX 268.34 per share Price / Cash Flow38.89 Book ValueGBX 2,630 per share Price / Book3.97Miscellaneous Outstanding Shares1,924,030,520Free FloatN/AMarket Cap£200.79 billion OptionableNot Optionable Beta0.17 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (LON:AZN) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share AstraZeneca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.